Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study | Gastroenterología y Hepatología (English Edition)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
IJMS | Free Full-Text | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
SciELO - Brasil - ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN'S DISEASE: results of a Latin American single-center observational study ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN'S DISEASE:
Adalimumab for the treatment of fistulas in patients with Crohn's disease | Gut
Refining the Role of TNF Antagonists for Crohn's Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study - The Lancet Gastroenterology & Hepatology
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis - Gastroenterology
![PDF] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e0cae5bfe02af6c86528d27d0b3501b3d52ce4ae/6-Figure2-1.png "PDF] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. | Semantic Scholar")
PDF] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. | Semantic Scholar
HUMIRA® (adalimumab) for Crohn's Disease in adults
M02-404 (CSR)
Design of the included studies of adalimumab for Crohn?s disease (CD).... | Download Scientific Diagram
Abbott's response to the Appraisal Consultation Document of adalimumab and infliximab for the treatment of Crohn's disease
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis | European Journal of Medical Research | Full Text
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - ScienceDirect
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population - Clinical Gastroenterology and Hepatology
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial - Baili Chen, Xiang Gao, Jie Zhong, Jianlin Ren, Xuan Zhu, Zhanju
Adalimumab (CLASSIC & CHARM trial - Crohn) | Digestive Disease Dashboard
IJMS | Free Full-Text | Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention
Design of the included studies of adalimumab for Crohn?s disease (CD).... | Download Scientific Diagram
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial - The Lancet
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
Frontiers | Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
